Drug intelligence / Profile preview

Ostave

Development stage: Unknown
Lead developer: Octave Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**Ostave** is an oral fixed-dose softgel capsule marketed by Octave Life Sciences. It contains calcitriol, calcium citrate, magnesium oxide, zinc sulfate monohydrate, methylcobalamin, L-methylfolate, and boron. The formulation combines active vitamin D signaling through calcitriol with calcium, mineral, and vitamin supplementation intended to support calcium homeostasis, bone mineralization, and nutritional repletion.

Brand names: Ostave

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Ostave.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ostave.

Explore the full profile